The Factor V Leiden mutation is associated with a higher blood haemoglobin concentration in women below 50 of the Malmö Thrombophilia Study (MATS)

Isma, Nazim; Breslin, Thomas A.; Lindblad, Bengt; Svensson, Peter

doi:10.1007/s11239-008-0293-z

Cited by 4 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the same line, Isma et al [76] also supported that thrombotic events may be considered a survival advantage against specific physiological conditions, specifically in women. In contrast to this idea, numerous publications revealed that the risk of suffering miscarriage during pregnancy in women carrying FVL is slightly increased (two or three upfold) as well as presenting complications derived of clotting episodes during pregnancy such as suffering DVT, pulmonary embolism, preeclampsia, slow fetal growth, and/or early separation of the placenta from the uterine wall (placental abruption) [77, 78].…”

Section: Factor V Leiden and Inflammation: Infection Sepsis And mentioning

confidence: 91%

Factor V Leiden and Inflammation

2012

View full text Add to dashboard Cite

Factor V Leiden, is a variant of human factor V (FV), also known as proaccelerin, which leads to a hypercoagulable state. Along these years, factor V Leiden (FVL) has been studied from the pathophysiologic point of view, and research has been focused on finding clinical approaches for the management of the FVL associated to a trombophilic state. Less attention has been paid about the possible role of FVL in inflammatory conditions known to be present in different disorders such as uremia, cirrhosis, liver transplantation, depression as well as sepsis, infection or, inflammatory bowel disease (IBD). Whether platelet FVL will increase the activation of coagulation and/or in which proportion is able to determine the final outcome in the previously mentioned inflammatory conditions is a subject that remains uncertain. This paper will review the association of FVL with inflammation. Specifically, it will analyze the important role of the endothelium and the contribution of other inflammatory components involved at both the immune and vascular levels. This paper will also try to emphasize the importance of being a FVL carrier in associations to diseases where a chronic inflammation occurs, and how this condition may be determinant in the progression and outcome of a specific clinic situation.

show abstract

Section: Factor V Leiden and Inflammation: Infection Sepsis And mentioning

confidence: 91%

Factor V Leiden and Inflammation

2012

View full text Add to dashboard Cite

show abstract

“…In one of the Swedish cohorts, FVL carriers had higher values of haemoglobin and ferritin early in pregnancy as well as less selfreported menstrual blood loss (16). Another group reported a difference between FVL carriers and non-carriers in haemoglobin values in pre-menopausal women, whereas the difference was absent in men and post-menopausal women (17). These findings suggest lower menstrual blood loss in FVL carriers.…”

Section: Beneficial Traitsmentioning

confidence: 93%

“…Survival benefits mainly relate to haemorrhage and inflammation although data are conflicting, especially on inflammation. Nevertheless FVL might be associated with: less acute blood loss, less menstrual blood loss, decreased risk of intracranial haemorrhage, milder phenotypes of haemophilia, higher survival in and lower susceptibility to severe sepsis, higher survival in acute respiratory distress syndrome (ARDS), decreased diabetic nephropathy, improved embryo implantation, a higher sperm count and higher fecundity in both men and women (see ▶ Table 1) (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25).…”

Section: Introductionmentioning

confidence: 99%

Evolution of Factor V Leiden

Mens¹,

Levi²,

Middeldorp³

2013

Thromb Haemost

View full text Add to dashboard Cite

Factor V Leiden is a procoagulant mutation associated with venous and arterial thrombosis and pregnancy complications. Its high prevalence of 5% in Caucasians suggests that there are evolutionary benefits as well. Carriers are indeed reported to have various advantageous phenotypes related to haemostasis, inflammation and fertility: less acute blood loss; less menstrual blood loss; decreased risk of intracranial haemorrhage; milder phenotypes of haemophilia; higher survival in and lower susceptibility to severe sepsis; higher survival in acute respiratory distress syndrome; less severe diabetic nephropathy and higher fecundity in both men and women. Not all these associations come from high quality adequately powered studies and many have not been confirmed by further research. The evolutionary influence of the alleged associations varies and is difficult to establish, partly due to a shift over time in risk factors of the diseases concerned. For most of the phenotypes possible mechanistic explanations can be provided. The procoagulant phenotype and perhaps also certain pregnancy complications follow from activated protein C (APC) resistance. Elevated APC levels possibly mediate anti-inflammatory effects. Higher sperm counts and more successful embryo implantation seem to play a role in the increased fecundity.

show abstract

“…Subsequently, the same authors demonstrated that carriership of FV Leiden was associated with higher hemoglobin and serum ferritin levels in early pregnancy and reduced menstrual blood loss, 35 suggesting that the FV Leiden mutation might have conferred an evolutionary advantage to women by protecting them against bleeding at parturition and menses. In accordance with this hypothesis were the published results of the Malmo Thrombophilia Study (MATS) 36 in 2009 in which female patients > 50 years of age with FV Leiden mutation had significantly higher median hemoglobin levels (133 versus 126 g/L; p < 0.001) compared with female patients < 50 years without FV Leiden. However, a prospective study did not confirm the protective effect of FV Leiden on pregnancy-related blood loss.…”

Section: Factor V Leiden and Evolutionmentioning

confidence: 63%

Factor V Leiden in Women: A Thrombotic Risk Factor or an Evolutionary Advantage?

Franchini

Lippi²

2011

Semin Thromb Hemost

View full text Add to dashboard Cite

Factor V Leiden is a common gain-of-function gene mutation resulting in a genetic predisposition to thromboembolic complications. Growing evidence in the literature indicates an interaction between factor V Leiden thrombophilia and acquired prothrombotic conditions such as contraceptive use or hormone replacement therapy, resulting in an increased risk of venous thromboembolism (VTE). Similarly, when combined with the prothrombotic influence of pregnancy, women who are carriers of factor V Leiden are faced with an increased risk of adverse pregnancy outcomes, including VTE, pre-eclampsia, fetal loss, placental abruption, and fetal growth restriction. The results of the most important meta-analyses on the relationship between inherited (factor V Leiden) and acquired thrombophilia in women are analyzed in this review, along with the possible evolutionary role of this mutation.

show abstract

The Factor V Leiden mutation is associated with a higher blood haemoglobin concentration in women below 50 of the Malmö Thrombophilia Study (MATS)

Cited by 4 publications

References 15 publications

Factor V Leiden and Inflammation

Factor V Leiden and Inflammation

Evolution of Factor V Leiden

Factor V Leiden in Women: A Thrombotic Risk Factor or an Evolutionary Advantage?

Contact Info

Product

Resources

About